Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Cinzia Volpari
A Proprotein Convertase Subtilisin-Like/Kexin Type 9 (PCSK9) C-Terminal Domain Antibody Antigen-Binding Fragment Inhibits PCSK9 Internalization and Restores Low Density Lipoprotein Uptake
Journal of Biological Chemistry
Biochemistry
Cell Biology
Molecular Biology
Related publications
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation
Journal of Biological Chemistry
Biochemistry
Cell Biology
Molecular Biology
Cost Effectiveness of Proprotein Convertase Subtilisin/ Kexin Type 9 (PCSK9) Inhibitors
Cardiovascular Disorders and Medicine
PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Status and Protection Against Ischemic Stroke
Circulation. Genomic and precision medicine
Genetics
Cardiovascular Medicine
Cardiology
Lipoprotein(a) and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors
Clinical Research in Cardiology Supplements
Nuclear Medicine
Radiology
Molecular Biology
Structural Biology
Imaging
Medicine
Lipoprotein(a) and Inhibitors of Proprotein Convertase Subtilisin/Kexin Type 9
Journal of Thoracic Disease
Pulmonary
Respiratory Medicine
Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism
Arteriosclerosis, Thrombosis, and Vascular Biology
Cardiovascular Medicine
Cardiology
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Deficiency Is Protective Against Venous Thrombosis in Mice
Scientific Reports
Multidisciplinary
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Alzheimer’s Disease: A Genetic and Proteomic Multi-Cohort Study
PLoS ONE
Multidisciplinary
Management of Patients Eligible for Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Economic Impact and Reform Proposals
Global and Regional Health Technology Assessment
Health Policy
